TRENDING NOW

“Pityrosporum folliculitis culminates with papules that are very small on the forehead and can be seen in a shawl-like distribution over people's bodies, whether it's the face, the back and the chest, or just the facial area. I cannot tell you the number of patients that have pityrosporum folliculitis who are responsive to ketoconazole… In my practice I generally treat it for four to eight weeks, and sometimes it takes longer to get to a point at which the patient is cleared.”

—Joel Schlessinger, MD

WEIGHING THE ROLE OF MAINSTAY THERAPIES IN THE NEW TREATMENT PARADIGM FOR ACNE

Despite the lack of new molecules in the treatment of acne, continued inquiries into the use and benefit of current and mainstay therapies are challenging old paradigms of therapy. One agent that is in need of a new approach is benzoyl peroxide (BP), according to Practical Dermatology editorial board member, Leon Kircik, MD. In a new article for the June issue of the Journal of Drugs in Dermatology, Dr. Kircik notes that combining BP with a topical antibiotic in a stable formulation has been proven in clinical trials to reduce total P. acnes count by 99.7 percent after one week of therapy. However, he goes on to observe that researchers have begun to notice BP's benefits as a monotherapy in the treatment of acne, suggesting that it works rapidly on P. acnes without causing antibiotic resistance. Thus, Dr. Kircik implores clinicians and researchers to reconsider the role of topical antibiotics such as clindamycin in the treatment paradigm of acne.

—J Drugs Dermatol. 2013 Jun 1; 12(6): s73-4

NEW FINDINGS SUPPORT THE NOTION OF “ACNE COSMETICA”

One of the more unlikely potential adverse events of cosmetic procedures, according to new research, is acne. Often referred to as “Acne Cosmetica,” post-adolescent acne resulting from cosmetic use has been the subject of some controversy in recent years, as data to show a direct link have been lacking. A new study, however, has shown a dose-dependent inverse association between cosmetic procedures and acne.

Researchers evaluated 910 post-adolescent patients with acne, as well as an equal number of matched controls, for exposure to cosmetics and cosmetic procedures. They stratified a cumulative cosmetic exposure index into four quarters of increasing exposure. Comparison of different cumulative exposure categories with the lowest exposure category showed that the odds ratios progressively declined as cosmetic exposure increased. The investigators concluded that overall cosmetic use was negatively associated with post-adolescent acne. They noted the term “acne cosmetica” is therefore appropriate, since some cosmetics may indeed cause acne.

—Dermatology. 2013 Jul 10

BY THE NUMBERS:64.4

The percentage of patients who were rated as responders, after six months of treatment with the dermal filler Artefill (Suneva Medical) for atrophic acne scars. In the randomized, double-blinded, controlled study, patients needed to exhibit a two-point improvement on a four-point Acne Scare Response Scale (ASRS) for at least half of scars treated—a 50 percent improvement rate. Full results from the study will be published, according to Suneva. ArteFill is indicated for the correction of nasolabial folds, but the company is seeking FDA approval for an indication of treatment of acne scars, as well.